Pink Slips for Genentech's Bay Area Employees
When Roche bought Genentech in March, layoffs were expected, and now the company has begun downsizing at Genentech?s South San Francisco headquarters.
When Roche bought Genentech in March, layoffs were expected, and now the company has begun downsizing at Genentech’s South San Francisco headquarters. So far the cuts have affected "less than one percent" of Genentech's 8,250 Bay Area employees, the company told the San Francisco Chronicle.
The reductions, which are occurring through a combination of voluntary buyouts and layoffs, focus on late-stage drug development and corporate administration, the Chronicle reported. There will be “little to no” job loss in manufacturing and all six of the Genentech’s manufacturing and distribution sites will stay open.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
